Rapidly Progressive Dementia Following COVID-19 Vaccination

 A previously healthy woman in her 60s had mild fever and uneventful course after the 1st dose of ChAdOx1 nCoV-19 vaccine, but developed behavioral problems and refusal to take food, one day after receiving the second dose of ChAdOx1 nCoV-19 vaccination (dose interval 84 days). Her condition progressed rapidly with onset of confusion, forgetfulness, and hallucinations within the next 5 days. Over the next two days, the patient developed difficulty in walking and echolalia. She was prescribed amantadine, trihexyphenidyl and clonazepam by a local practitioner but she showed further deterioration in the form of irritability, incoherent speech, aggravated forgetfulness, auditory and visual hallucinations, abnormal movements of limbs, and jaw and neck dystonia. The patient had a serum anti-Spike protein IgG titer of 1891.5 AU/mL (non-reactive<50 AU/mL) at 37 days post-second dose. An initial magnetic resonance imaging (MRI) of the brain had revealed FLAIR hyperintensity in bilateral caudate heads which showed diffusion restriction and also patchy diffusion restriction in the left posterior parietal and occipital gyri (Fig. 1A). 


In the absence of clinical improvement, a repeat imaging was performed after 16 days (Fig. 1B) which revealed an increase in the degree of FLAIR hyperintensity and diffusion restriction in bilateral caudate nuclei as well as involvement of bilateral putamina, with diffuse diffusion restriction in the cerebral cortex in bilateral hemispheres. A cortical ribboning pattern of hyperintensity was observed in the diffusion image. 

An electroencephalogram (EEG) revealed bilateral biphasic and triphasic sharp wave periodic discharges of around one Hz, with slowing of background activity (Fig. 1C). The patient was managed conservatively with a trial of dexamethasone, empirical broad-spectrum antibiotics, and antiepileptics but had no significant improvement. Later, bromocriptine was added which resulted in some improvement in her limb rigidity. However, overall neurologic deterioration continued over the next two weeks, and she developed respiratory distress and shock to which she finally succumbed after one month of admission. The possibility of a secondary infection leading to sepsis and shock, and eventually resulting in fatality exists. 

READ MORE

Another case of a 30-year-old woman presented with rapidly progressive dementia 1 month after COVID-19


REFERENCE

Chakrabarti SS, Tiwari A, Jaiswal S, Kaur U, Kumar I, Mittal A, Singh A, Jin K, Chakrabarti S. Rapidly Progressive Dementia with Asymmetric Rigidity Following ChAdOx1 nCoV-19 Vaccination. Aging Dis. 2022 Jun 1;13(3):633-636. doi: 10.14336/AD.2021.1102. PMID: 35656106; PMCID: PMC9116920.

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

Navigating the Tripledemic: JN.1, RSV, and Flu Update

Image
The respiratory viruses are out there.  Wastewater viral activity levels for COVID-19 , as reported by the Centers for Disease Control and Prevention, have reached the highest point since the Omicron surge in 2022. The levels are also high in Canada . The three primary respiratory illnesses continue to circulate at very high levels. But despite the triple threat of  SARS-Cov-2, respiratory syncytial virus ( RSV ) and the flu , there is a notable lack of community attention.   JN.1 (Pirola,  BA.2.86 ,  with additional L455S mutation, descending from a  de-escalated  variant of concern BA.2), initially detected on August 25 2023, has evolved from a variant under monitoring to a  variant of interest. Variants like Acrux (XBB.2.3, that began to spread worldwide soon after WHO declared the end of the pandemic) are  no longer relevant , but a few now less prevalent variants such as  Centaurus  (BA.2.75) and XBB, a hybrid of Centaurus with BA.2 lineage, that  gave rise to  Eris , its descend
Read more

The offshoots of JN.1 in the Evolutionary Trajectory of COVID-19

Image
While the current SARS-COV-2 viral activity levels may seem reassuring ( back to the levels seen in October-November 2023 ), the evolving world of JN.1 offshoots, where the next generation of variants is taking shape, presents a compelling case for anticipating the potential challenges that lie ahead.  From the widespread presence of JN.1.16 across continents to the emerging dominance of JN.1.13 in the U.S., the current variant landscape is rapidly shifting, although the potential implications for the future are not quite clear.  The roots of the pandemic can be traced back to lineage A, with many initial sequences originating from China and subsequently spreading globally, including to regions such as South East Asia, Japan, South Korea, Australia, the USA, and Europe. Lineage B followed as the second major haplotype, with subsequent evolutions leading to the emergence of various sublineages. In 2020, we witnessed the emergence of variants such as Alpha (B.1.1.7) and Delta (B.1.617.2
Read more